| Literature DB >> 27061135 |
Parul Mittal1,2, Manuela Klingler-Hoffmann1,2, Georgia Arentz1,2, Lyron Winderbaum1,2, Noor A Lokman1,3, Chao Zhang1,2, Lyndal Anderson4, James Scurry5, Yee Leung6, Colin Jr Stewart6, Jonathan Carter7, Gurjeet Kaur8, Martin K Oehler3,9, Peter Hoffmann1,2.
Abstract
Metastasis is a crucial step of malignant progression and is the primary cause of death from endometrial cancer. However, clinicians presently face the challenge that conventional surgical-pathological variables, such as tumour size, depth of myometrial invasion, histological grade, lymphovascular space invasion or radiological imaging are unable to predict with accuracy if the primary tumour has metastasized. In the current retrospective study, we have used primary tumour samples of endometrial cancer patients diagnosed with (n = 16) and without (n = 27) lymph node metastasis to identify potential discriminators. Using peptide matrix assisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI), we have identified m/z values which can classify 88% of all tumours correctly. The top discriminative m/z values were identified using a combination of in situ sequencing and LC-MS/MS from digested tumour samples. Two of the proteins identified, plectin and α-Actin-2, were used for validation studies using LC-MS/MS data independent analysis (DIA) and immunohistochemistry. In summary, MALDI-MSI has the potential to identify discriminators of metastasis using primary tumour samples.Entities:
Keywords: Biomarker; Endometrial cancer; Lymph node metastasis; Proteomics
Mesh:
Substances:
Year: 2016 PMID: 27061135 DOI: 10.1002/pmic.201500455
Source DB: PubMed Journal: Proteomics ISSN: 1615-9853 Impact factor: 3.984